Adults 18 to 80, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Primary· Day 1 up to Day 30
Participants with TEAEs
Group
Value
95% CI
Suzetrigine (SUZ)
94
Participants with SAEs
Group
Value
95% CI
Suzetrigine (SUZ)
2
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) ScaleSecondary· Day 14 or at Pain Resolution, whichever occurs first
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported.
Group
Value
95% CI
Suzetrigine (SUZ)
83.2
Adverse events — posted to ClinicalTrials.gov
Time frame: Day 1 up to Day 30.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
· recruiting
NCT07454993 — The Effect of Music During Colonoscopy
· NA
· recruiting
Other Vertex Pharmaceuticals Incorporated trials
Trials by the same sponsor.
NCT05951205 — Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Ge
· Phase 3
· withdrawn
NCT07501702 — A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
· Phase 2
· not yet recruiting
NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
· Phase 1
· recruiting
NCT07378865 — Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
· Phase 1
· recruiting
NCT07349394 — Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated
Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05661734.